Paper19877181
Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety.
Vitale A and 7 others. Hepatology, 2010. Cited by 91 papers, by iCite.
Cite this record
ConductScience Library. Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety. Papers, record 19877181. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19877181
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Benzenesulfonates | Major topic |
| Carcinoma, Hepatocellular | Major topic |
| Pyridines | Major topic |
| Cost-Benefit Analysis | |
| Humans | |
| Liver Transplantation | |
| Markov Chains | |
| Models, Theoretical | |
| Monte Carlo Method | |
| Niacinamide | |
| Phenylurea Compounds | |
| Quality-Adjusted Life Years | |
| Sorafenib | |
| Treatment Outcome | |
| Waiting Lists |
Source PubMed
Comments and corrections4
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 20034046 | Multifaceted perspective of the waiting list for liver transplantation: the value of pharmacokinetic models. | https://conductscience.org/library/papers/20034046 | PubMed |
| Comment in | 20041410 | Hepatocellular carcinoma: sorafenib before liver transplantation? | https://conductscience.org/library/papers/20041410 | PubMed |
| Comment in | 20812364 | Sorafenib therapy in patients with hepatocellular carcinoma before liver transplantation. | https://conductscience.org/library/papers/20812364 | PubMed |
| Comment in | 22127280 | Sorafenib use while waiting for liver transplant: we still need to wait. | https://conductscience.org/library/papers/22127280 | PubMed |
Cited by34
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 91 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41104208 | Neoadjuvant systemic therapy for hepatocellular carcinoma: challenges and opportunities-a narrative review. | Hepatobiliary Surg Nutr | 2025 | https://conductscience.org/library/papers/41104208 | PubMed |
| 38627031 | British Society of Gastroenterology guidelines for the management of hepatocellular carcinoma in adults. | Gut | 2024 | https://conductscience.org/library/papers/38627031 | PubMed |
| 37077517 | Radiological findings in non-surgical recurrent hepatocellular carcinoma: From locoregional treatments to immunotherapy. | World J Gastroenterol | 2023 | https://conductscience.org/library/papers/37077517 | PubMed |
| 36498435 | The First 30 Years of the Universal Hepatitis-B Vaccination-Program in Italy: A Health Strategy with a Relevant and Favorable Economic-Profile. | Int J Environ Res Public Health | 2022 | https://conductscience.org/library/papers/36498435 | PubMed |
| 36438781 | Neo-Adjuvant Use of Sorafenib for Hepatocellular Carcinoma Awaiting Liver Transplantation. | Transpl Int | 2022 | https://conductscience.org/library/papers/36438781 | PubMed |
| 36068876 | Neoadjuvant Therapy for Hepatocellular Carcinoma. | J Hepatocell Carcinoma | 2022 | https://conductscience.org/library/papers/36068876 | PubMed |
| 35368665 | A Novel Prognostic Model for Identifying the Risk of Hepatocellular Carcinoma Based on Angiogenesis Factors. | Front Genet | 2022 | https://conductscience.org/library/papers/35368665 | PubMed |
| 35222709 | Combination treatment with sorafenib and wh-4 additively suppresses the proliferation of liver cancer cells. | Exp Ther Med | 2022 | https://conductscience.org/library/papers/35222709 | PubMed |
| 34631511 | Association Between Adjuvant Sorafenib and the Prognosis of Patients With Hepatocellular Carcinoma at a High Risk of Recurrence After Radical Resection. | Front Oncol | 2021 | https://conductscience.org/library/papers/34631511 | PubMed |
| 34400051 | Chinese expert recommendations on management of hepatocellular carcinoma during COVID-19 pandemic: a nationwide multicenter survey. | HPB (Oxford) | 2022 | https://conductscience.org/library/papers/34400051 | PubMed |
| 34358718 | National Trends and Waitlist Outcomes of Locoregional Therapy Among Liver Transplant Candidates With Hepatocellular Carcinoma in the United States. | Clin Gastroenterol Hepatol | 2022 | https://conductscience.org/library/papers/34358718 | PubMed |
| 32399593 | Recommendations for medical care of oncological patients during the COVID-19 epidemic: experiences from China. | Updates Surg | 2020 | https://conductscience.org/library/papers/32399593 | PubMed |
| 31573053 | Economic Implications of Hepatocellular Carcinoma Surveillance and Treatment: A Guide for Clinicians. | Pharmacoeconomics | 2020 | https://conductscience.org/library/papers/31573053 | PubMed |
| 31391767 | Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma. | World J Gastroenterol | 2019 | https://conductscience.org/library/papers/31391767 | PubMed |
| 31185950 | A prospective clinical trial on sorafenib treatment of hepatocellular carcinoma before liver transplantation. | BMC Cancer | 2019 | https://conductscience.org/library/papers/31185950 | PubMed |
| 30840163 | Obtaining Optimal Long-Term Outcomes from Liver Transplantation for Hepatocellular Cancer. | Dig Dis Sci | 2019 | https://conductscience.org/library/papers/30840163 | PubMed |
| 30190965 | Liver transplantation for hepatocellular carcinoma: how far have we come and what is the future? | Hepat Oncol | 2014 | https://conductscience.org/library/papers/30190965 | PubMed |
| 29804373 | [The mechanism and current strategies for preventing the recurrence of hepatocellular carcinoma after liver transplantation]. | Zhonghua Gan Zang Bing Za Zhi | 2018 | https://conductscience.org/library/papers/29804373 | PubMed |
| 29467861 | Induction of apoptosis by an oleanolic acid derivative in SMMC-7721 human hepatocellular carcinoma cells is associated with mitochondrial dysfunction. | Oncol Lett | 2018 | https://conductscience.org/library/papers/29467861 | PubMed |
| 28799575 | Comparison of outcomes between SBRT, yttrium-90 radioembolization, transarterial chemoembolization, and radiofrequency ablation as bridge to transplant for hepatocellular carcinoma. | Adv Radiat Oncol | 2016 | https://conductscience.org/library/papers/28799575 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/19877181
GET https://conductscience.org/api/papers/v1/19877181/cited_by?page=2